Redcare Pharmacy Announces Significant Growth in German Rx Sales for Q3

Redcare Pharmacy has reported an 81% increase in Q3 Rx sales in Germany, with a remarkable 108% growth in September alone. In response to this growth and promising e-Rx metrics, the company plans to enhance its marketing efforts in Q4. The strategic decision is expected to further bolster Redcare Pharmacy's market leadership through increased profitable growth.

The full-year guidance for 2024 has been updated by the Management Board. Total Group sales are now anticipated to range between EUR 2.35 to 2.5 billion, with non-Rx sales expected to grow by 20-25%. However, a precise guidance for Rx sales remains unpredictable due to its dynamic nature.

The adjusted EBITDA margin outlook has been revised to 1.2-2.2%, highlighting a slight decrease from previous estimates. Additionally, MediService sales growth is projected at the lower half of single digits.